Welcome!

News Feed Item

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

NEW YORK, March 19, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability
http://www.reportlinker.com/p02052296/Epilepsy-Therapeutics-in-Asia-Pacific-Markets-to-2019---Treatment-Options-Enhanced-As-Novel-Next-Generation-AEDs-Show-Improved-Safety-and-Tolerability.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan. The report includes -
- A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options
- In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters
- A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target.
- Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action
- Multi-scenario forecasts of the epilepsy market from 2012 to 2019 in the four APAC regions
- In-depth analysis of licensing and co-development agreements and an overview of key agreements that could impact growth trends
- Key drivers and restraints that have had and are expected to have a significant impact upon the market

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Align your product portfolio to markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the anti-epileptic drugs market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
1 Table of Contents
1 Table of Contents 5

1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Disease Overview 8
2.2 Epidemiology 8
2.3 Symptoms 9
2.4 Etiology 10
2.5 Pathophysiology 10
2.6 Co-morbidities/Complications 11
2.7 Diagnosis 11
2.8 Prognosis 11
2.9 Treatment Efficacy 11
2.10 Treatment Options 12
2.10.1 Ion Channel Modulators 12
2.10.2 GABA-ergic Facilitation 12
2.10.3 Excitatory Amino Acid Inhibitors 12
2.10.4 Synaptic Modulators 12
2.11 Non-pharmacological Management 13
2.11.1 Lobectomy and Lesionectomy 13
2.11.2 Ketogenic Diet and Modified Atkins Diet 13

2.11.3 Vagus Nerve Stimulation 13
3 Epilepsy Therapeutic Landscape 14
3.1 Overview 14
3.2 Lyrica (pregabalin) 14
3.3 Lamictal (lamotrigine) 15
3.4 Keppra (levetiracetam) 16
3.5 Zonegran (zonisamide) 18
3.6 Vimpat (lacosamide) 19
3.7 Aptiom/Zebinix (eslicarbazepine acetate) 21
3.8 Fycompa (perampanel) 21
3.9 Trobalt/Potiga (ezogabine/retigabine) 22
3.10 Banzel/Inovelon (rufinamide) 23
3.11 Comparative Efficacy and Safety of Marketed Products 23
4 Pipeline for Epilepsy Therapeutics 26
4.1 Overall Pipeline 26
4.2 Pipeline by Mechanism of Action 28
4.3 Clinical Trials 29
4.3.1 Failure Rate 29
4.3.2 Patient Enrolment and Clinical Trial Size 31
4.3.3 Clinical Trial Duration 32
4.4 Promising Pipeline Candidates 33
4.4.1 Brivaracetam – UCB 33
4.4.2 Ganaxolone – Marinus Pharmaceuticals 33
5 Epilepsy Therapeutics Market Forecast to 2019 34
5.1 Geographical Markets 34
5.1.1 Key Asia-Pacific Markets 34
5.1.2 China 36

5.1.3 India 38
5.1.4 Japan 40
5.1.5 Australia 42
5.2 Drivers and Barriers 44
5.2.1 Drivers 44
5.2.2 Barriers 44
6 Deals and Strategic Consolidations 45
6.1 Deals Analysis 45
6.2 Research and Development Co-development Agreements 47
6.3 Research and Development Licensing Agreements 48
7 Appendix 50
7.1 Abbreviations 50
7.2 References 51
7.3 References for Heat Maps 55
7.4 Pipeline Products by Phase 56
7.4.1 Discovery 56
7.4.2 Preclinical 57
7.4.3 IND-filed and Phase 0 58
7.4.4 Phase I 58
7.4.5 Phase II 59
7.4.6 Phase III 60
7.4.7 Pre-registration 60
7.5 Market Forecasting Data Tables to 2019 61
7.5.1 Asia-Pacific 61
7.5.2 China 61
7.5.3 India 61
7.5.4 Japan 62
7.5.5 Australia 62

7.6 Research Methodology 62
7.6.1 Coverage 62
7.6.2 Secondary Research 63
7.6.3 Primary Research 63
7.6.4 Therapeutic Landscape 63
7.6.5 Geographical Landscape 66
7.6.6 Pipeline Analysis 66
7.7 Expert Panel Validation 66
7.8 Contact Us 66
7.9 Disclaimer 66

1.1 List of Tables
Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2013 8
Table 2: Epilepsy Therapeutics, Heat Maps for Efficacy and Safety of Marketed Products, References 55
Table 3: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Discovery), 2013 56
Table 4: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Preclinical), 2013 57
Table 5: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013 58
Table 6: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase I), 2013 58
Table 7: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase II), 2013 59
Table 8: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase III), 2013 60
Table 9: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Pre-registration), 2013 60
Table 10: Epilepsy Therapeutics, Asia-Pacific, Market Forecast, 2012–2019 61
Table 11: Epilepsy Therapeutics, China, Market Forecast, 2012–2019 61
Table 12: Epilepsy Therapeutics, India, Market Forecast, 2012–2019 61
Table 13: Epilepsy Therapeutics, Japan, Market Forecast, 2012–2019 62
Table 14: Epilepsy Therapeutics, Australia, Market Forecast, 2012–2019 62

1.2 List of Figures
Figure 1: Epilepsy Therapeutics, Epidemiology, Asia-Pacific, 2012 9
Figure 2: Epilepsy Therapeutics, Lyrica, Global, Revenue ($bn), 2013 15
Figure 3: Epilepsy Therapeutics, Lamictal, Global, Revenue ($m), 2009–2013 16
Figure 4: Epilepsy Therapeutics, Keppra, Global, Revenue ($bn), 2009–2013 17
Figure 5: Epilepsy Therapeutics, Zonegran, Global, Revenue ($m), 2009–2013 18
Figure 6: Epilepsy Therapeutics, Vimpat, Global, Revenue ($m), 2009–2013 20
Figure 7: Epilepsy Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013 24
Figure 8: Epilepsy Therapeutics, Global, Overall Pipeline Analysis, 2013 27
Figure 9: Epilepsy Therapeutics, Global, Pipeline Analysis, by Mechanism of Action, 2013 28
Figure 10: Epilepsy Therapeutics, Global, Clinical Trial Failure Rate, 2013 30
Figure 11: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Size, 2013 31
Figure 12: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Duration, 2013 32
Figure 13: Epilepsy Therapeutics, Asia-Pacific, Market Size, 2012–2019 35
Figure 14: Epilepsy Therapeutics, China, Market Size, 2012–2019 37
Figure 15: Epilepsy Therapeutics, India, Market Size, 2012–2019 39
Figure 16: Epilepsy Therapeutics, Japan, Market Size, 2012–2019 41
Figure 17: Epilepsy Therapeutics, Australia, Market Size, 2012–2019 43
Figure 18: Epilepsy Therapeutics, Deals by Region, Value and Year, 2006–2013 45
Figure 19: Epilepsy Therapeutics, Deals by Molecule Type and Mechanism of Action, 2006–2013 46
Figure 20: Epilepsy Therapeutics, Co-development Deals, Territory, 2006–2013 47
Figure 21: Epilepsy Therapeutics, Licensing Deals, by Territory, 2006–2013 48
Figure 22: GBI Research Market Forecasting Model 65

To order this report: Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability
http://www.reportlinker.com/p02052296/Epilepsy-Therapeutics-in-Asia-Pacific-Markets-to-2019---Treatment-Options-Enhanced-As-Novel-Next-Generation-AEDs-Show-Improved-Safety-and-Tolerability.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
SYS-CON Events announced today that Dataloop.IO, an innovator in cloud IT-monitoring whose products help organizations save time and money, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Dataloop.IO is an emerging software company on the cutting edge of major IT-infrastructure trends including cloud computing and microservices. The company, founded in the UK but now based in San Fran...
Join Impiger for their featured webinar: ‘Cloud Computing: A Roadmap to Modern Software Delivery’ on November 10, 2016, at 12:00 pm CST. Very few companies have not experienced some impact to their IT delivery due to the evolution of cloud computing. This webinar is not about deciding whether you should entertain moving some or all of your IT to the cloud, but rather, a detailed look under the hood to help IT professionals understand how cloud adoption has evolved and what trends will impact th...
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, contrasted how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He showed how the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He also demoed building immutable pipelines in the cloud ...
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Businesses and business units of all sizes can benefit from cloud computing, but many don't want the cost, performance and security concerns of public cloud nor the complexity of building their own private clouds. Today, some cloud vendors are using artificial intelligence (AI) to simplify cloud deployment and management. In his session at 20th Cloud Expo, Ajay Gulati, Co-founder and CEO of ZeroStack, will discuss how AI can simplify cloud operations. He will cover the following topics: why clou...
"We are a custom software development, engineering firm. We specialize in cloud applications from helping customers that have on-premise applications migrating to the cloud, to helping customers design brand new apps in the cloud. And we specialize in mobile apps," explained Peter Di Stefano, Vice President of Marketing at Impiger Technologies, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, discussed why and how ReadyTalk diverted from healthy revenue and mor...
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Dave McCarthy, Director of Products at Bsquare Corporation; Alan Williamson, Principal...